EGFR

Ongoing clinical trials and approved products targeting EGFR, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials
4ongoing imaging trials
0approved products

Target note

Full name
Epidermal growth factor receptor (EGFR)
Nature
Receptor tyrosine kinase.
Normal expression
Liver, skin.
Value
Assessing expression before anti-EGFR treatment; guiding surgery (dual-modality tracers).
Approaches
Panitumumab or cetuximab labeled with ¹¹¹In or ⁸⁹Zr.
Indications explored
Head and neck, colorectal and lung cancers.
Points of caution
Hepatic uptake; late imaging with antibodies.

Ongoing imaging trials · 4Open in the radar →

TrialPhaseStatusSponsorCountries
EGFR tracersNCT04235114 · ColorectalPhase 2RecruitingUniversity of Saskatchewan1
EGFR tracersNCT05945875 · Head and neckPhase 1RecruitingVanderbilt-Ingram Cancer Center1
EGFR tracersNCT07741643 · Head and neckPhase 1RecruitingVanderbilt-Ingram Cancer Center1
EGFR tracersNCT05183048 · Head and neckPhase 1RecruitingUniversity of Alabama at Birmingham1

Cite this page

EGFR. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/egfr/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.